Table 2 Baseline data and clinical characteristics of the study subjects
Feature | RA patient (n = 250) | Healthy control (n = 250) | P value |
|---|---|---|---|
Age | 53.15 ± 10.89 | 49.2 ± 15.7 | > 0.05 |
Gender | |||
Female | 205 (82%) | 202 (80.8%) | > 0.05 |
Male | 45 (18%) | 48 (19.2%) | |
Smoking | |||
Yes | 44 (17.6%) | 41 (16.4%) | > 0.05 |
No | 206 (82.4%) | 209 (83.6%) | |
BMI (Kg/m 2 ) | 29.41 ± 4.90 | - | - |
Anti-CCP (mg/L) | 58.74 ± 41.19 | - | - |
RF level (mg/L) | 41.07 ± 33.1 | - | - |
ESR (mm/h) | 21.63 ± 18.8 |  | - |
CRP (mg/L) | 3.47 ± 2.63 | - | - |
DAS28 | 4.83 ± 1.01 | - | - |
Corticosteroid use; n (%) | 185 (74%) | - | - |
DMARD use; n (%) | 138 (55.2%) | - | - |
NSAID use; n (%) | 211 (84.4%) | - | - |